Table 1.
Baseline demographics IFX-naïve IBD population.
| IBD naïve (n = 1763) | IFX-RP (n = 785) | IFX-dyyb (n = 441) | IFX-abda (n = 537) | P values | |||
|---|---|---|---|---|---|---|---|
| Mean ± SD | 95% CI | Mean ± SD | 95% CI | Mean ± SD | 95% CI | ||
| Age at index (yr) | 51.6 ± 16.9 | 50.4–52.8 | 51.1 ± 16.6 | 49.5, 52.6 | 53.4 ± 16.5 | 52–54.7 | .072 |
| Gender | N | Col % (95% CI) | N | Col % (95% CI) | n | Col % (95% CI) | |
| Male | 697 | 88.8 (88.6, 91) | 392 | 88.9 (86, 91.8) | 468 | 87.2 (84.3, 90) | .601 |
| Race | N | Col % (95% CI) | N | Col % (95% CI) | n | Col % (95% CI) | |
| White | 586 | 74.6 (71.6, 77.7) | 311 | 70.5 (66.3, 74.8) | 390 | 72.6 (68.9, 76.4) | .287 |
| Black | 102 | 13 (10.6, 15.4) | 78 | 17.7 (14.1, 21.3) | 75 | 14 (11, 16.9) | .075 |
| Others | 29 | 3.7 (2.4, 5) | 9 | 2 (0.7, 3.4) | 17 | 3.2 (1.7, 4.7) | .278 |
| Missing | 68 | 8.7 (7.8, 12) | 43 | 9.8 (7, 12.5) | 55 | 10.2 (7.7, 12.8) | .603 |
| Ethnicity | N | Col % (95% CI) | N | Col % (95% CI) | n | Col % (95% CI) | |
| Hispanic | 57 | 7.3 (5.5, 9.1) | 29 | 6.6 (4.3, 8.9) | 34 | 6.3 (4.3, 8.4) | .785 |
| Non-Hispanic | 650 | 82.8 (80.2, 85.4) | 358 | 81.2 (77.5, 84.8) | 425 | 79.1 (75.7, 82.6) | .245 |
| Missing | 78 | 9.9 (7.8, 12) | 54 | 12.2 (9.2, 15.3) | 78 | 14.5 (11.5, 17.5) | .040 |
| BMI at index | 28.6 ± 5.4 | 28.2–28.9 | 28.7 ± 5.7 | 28.2–29.3 | 28.9 ± 5.6 | 28.4–29.4 | .522 |
| Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | ||
|---|---|---|---|---|---|---|---|
| DCCI | 0.7 ± 1.3 | 0 (0–1) | 0.7 ± 1.3 | 0 (0–1) | 0.8 ± 1.4 | 0 (0–1) | .186 |
| Smoking | N | Col % (95% CI) | N | Col % (95% CI) | N | Col % (95% CI) | |
| Current | 204 | 26 (22.9, 29.1) | 102 | 23.1 (19.2, 27.1) | 111 | 20.7 (17.3, 24.1) | .079 |
| Former | 249 | 31.7 (28.5, 35) | 145 | 32.9 (28.5, 37.3) | 224 | 41.7 (37.5, 45.9) | .000 |
| Never | 330 | 42 (38.6, 45.5) | 192 | 43.5 (38.9, 48.2) | 202 | 37.6 (33.5, 41.7) | .131 |
| Missing | 2 | 0.3 (0.03, 0.9) | 2 | 0.5 (0.1, 1.6) | 0 | 0 | .325 |
| IBD | N | Col % (95% CI) | N | Col % (95% CI) | n | Col % (95% CI) | |
| Ulcerative colitis | 351 | 44.7 (41.2, 48.2) | 200 | 45.4 (40.7, 50) | 226 | 42.1 (37.9, 46.3) | .526 |
| Crohn’s disease | 434 | 55.3 (51.8, 58.8) | 241 | 54.6 (50, 59.3) | 311 | 57.9 (53.7, 62.1) | .526 |
| Previous medication | N | Col % (95% CI) | N | Col % (95% CI) | n | Col % (95% CI) | |
| Corticosteroid | 280 | 35.7 (32.3, 39) | 177 | 40.1 (35.6, 44.7) | 185 | 34.5 (30.4, 38.5) | .156 |
| 5-ASA | 437 | 55.7 (52.2, 59.1) | 258 | 58.5 (53.9, 63.1) | 300 | 55.9 (51.7, 60.1) | .599 |
| Non-TNFi biologics | 71 | 9.0 (7, 11.1) | 29 | 6.6 (4.3, 8.9) | 37 | 6.9 (4.8, 9) | .198 |
| Non-IFX TNFi | 278 | 35.4 (32.1, 38.8) | 174 | 39.5 (34.9, 44) | 193 | 35.9 (31.9, 40) | .345 |
| JAK inhibitor | 22 | 2.8 (1.7, 4) | 22 | 5 (3, 7) | 16 | 3 (1.5, 4.4) | .104 |
| OSM | 313 | 39.9 (36.5, 43.3) | 182 | 41.3 (36.7, 45.9) | 209 | 38.9 (34.8, 43) | .756 |
Note: Continuous variables were evaluated using ANOVA, and categorical or dichotomous outcomes were evaluated using Chi-square.
5-ASA = 5-aminosalicylates, BMI = body mass index, DCCI = Deyo–Charlson comorbidity index, IBD = inflammatory bowel disease, JAK = Janus kinase inhibitors, OSM = oral small molecule (other than JAK inhibitors), TNFi = tumor necrosis factor inhibitor.